



State of Louisiana
Louisiana Department of Health
Bureau of Health Services Financing

MEMORANDUM

DATE: December 12, 2019

TO: Louisiana Medicaid Fee-for-Service Pharmacy Program and
Managed Care Organizations

FROM: Melwyn Wendt
Pharmacy Director

SUBJECT: Point of Sale Edits

Effective March 2, 2020, the Louisiana Medicaid Fee-for-Service (FFS) Pharmacy Program and Managed Care Organizations (MCOs) will update the following clinical edits at Point of Sale (POS). The updates apply to FFS and Medicaid MCOs (Aetna, AmeriHealth Caritas, Healthy Blue, Louisiana Healthcare Connections and United Healthcare). This measure was approved at the November 2019 meeting of the Louisiana Drug Utilization Review Board.

Additional Diagnosis Code Requirements:

Medication	DX Code	Indication
Sunosi™(solriamftol)	G47.33	Obstructive sleep apnea
	G47.4*	Narcolepsy
Wakix®(pitolisan)	G47.4*	Narcolepsy
Rilutek® (riluzole)	G12.21	Amyotrophic lateral sclerosis
Tiglutik™ (riluzole)	G12.21	Amyotrophic lateral sclerosis
Radicava® (edaravone)	G12.21	Amyotrophic lateral sclerosis

Medication	DX Code	Indication
Onpattro® (patisiran)	E85.1	Neuropathic heredofamilial amyloidosis
Tegsedi™ (inotersen)	E85.1	Neuropathic heredofamilial amyloidosis
Myobloc® (rimabotulinumtoxinB)	K11.7	Chronic sialorrhea
Egrifta® and Egrifta SV® (tesamorelin)	B20	Human immunodeficiency virus [HIV] disease

Additional POS edits:

Medication	POS Edit	Details
Vyndamax™ (tafamidis)	Quantity limit	30 capsules per 30 days
Vyndaqel® (tafamidis meglumine)	Quantity limit	120 capsules per 30 days
Reclast® (zoledronic acid)	Quantity limit	1 vial in 365 days
Nuedexta® (dextromethorphan hydrobromide/quinidine sulfate)	Quantity limit	60 tabs per 30 days
Sunosi™ (solriamftol)	Therapeutic duplication	Therapeutic duplication with stimulants [Depending on the stimulant, either NO override or override at POS after dr consultation]
Wakix® (pitolisan)	Therapeutic duplication	Therapeutic duplication with stimulants [Depending on the stimulant, either NO override or override at POS after dr consultation]
Sunosi™ (solriamftol)	Concurrent use	Concurrent use with sedative hypnotics [Override at POS]
Wakix® (pitolisan)	Concurrent use	Concurrent use with sedative hypnotics [Override at POS]
Sunosi™ (solriamftol)	Age limit	Age Limit= 18 years of age or older [No override]
Wakix® (pitolisan)	Age limit	Age Limit= 18 years of age or older [No override]
Ryblesus® (semaglutide)	Prior Drug Use Req.	90 days prior use of metformin, or 60 days prior use of GLP1 inhibitor